1. Advanced management of ventricular arrhythmias in chronic Chagas cardiomyopathy
- Author
-
David Santacruz, MD, Fernando Rosas, MD, Carina Abigail Hardy, MD, Diego Ospina, MD, Andrea Nathalie Rosas, MD, Juan Manuel Camargo, MD, Juan José Bermúdez, MD, Juan Felipe Betancourt, MD, Víctor Manuel Velasco, MD, and Mario D. González, MD, FHRS
- Subjects
Antiarrhythmic treatment ,Cardiomyopathy ,Catheter ablation ,Chagas disease ,Endo-epicardial approach ,Implantable cardioverter-defibrillator ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Chagas cardiomyopathy is a parasitic infection caused by Trypanosoma cruzi. Structural and functional abnormalities are the result of direct myocardial damage by the parasite, immunological reactions, dysautonomia, and microvascular alterations. Chronic Chagas cardiomyopathy (CCC) is the most serious and important manifestation of the disease, affecting up to 30% of patients in the chronic phase. It results in heart failure, arrhythmias, thromboembolism, and sudden cardiac death. As in other cardiomyopathies, scar-related reentry frequently results in ventricular tachycardia (VT). The scars typically are located in the inferior and lateral aspects of the left ventricle close to the mitral annulus extending from endocardium to epicardium. The scars may be more prominent in the epicardium than in the endocardium, so epicardial mapping and ablation frequently are required. Identification of late potentials during sinus rhythm and mid-diastolic potentials during hemodynamically tolerated VT are the main targets for ablation. High-density mapping during sinus rhythm can identify late isochronal regions that are then targeted for ablation. Preablation cardiac magnetic resonance imaging with late enhancement can identify potentials areas of arrhythmogenesis. Therapeutic alternatives for VT management include antiarrhythmic drugs and modulation of the cardiac autonomic nervous system.
- Published
- 2021
- Full Text
- View/download PDF